Taysha Gene Therapies Price to Book Ratio 2020-2024 | TSHA
Historical price to book ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The current price to book ratio for Taysha Gene Therapies as of November 01, 2024 is 2.63.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Taysha Gene Therapies Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2024-11-01 |
1.53 |
|
2.83 |
| 2024-06-30 |
2.24 |
$0.54 |
4.14 |
| 2024-03-31 |
2.87 |
$0.29 |
9.97 |
| 2023-12-31 |
1.77 |
$0.40 |
4.42 |
| 2023-09-30 |
3.16 |
$-0.26 |
-12.03 |
| 2023-06-30 |
0.66 |
$-0.58 |
-1.15 |
| 2023-03-31 |
0.80 |
$-0.24 |
-3.39 |
| 2022-12-31 |
2.26 |
$0.02 |
150.67 |
| 2022-09-30 |
1.93 |
$0.27 |
7.14 |
| 2022-06-30 |
3.72 |
$0.80 |
4.67 |
| 2022-03-31 |
6.52 |
$1.32 |
4.95 |
| 2021-12-31 |
11.65 |
$2.48 |
4.70 |
| 2021-09-30 |
18.62 |
$3.65 |
5.10 |
| 2021-06-30 |
21.20 |
$4.86 |
4.36 |
| 2021-03-31 |
20.30 |
$5.90 |
3.44 |
| 2020-12-31 |
26.54 |
$6.66 |
3.99 |
| 2020-09-30 |
22.40 |
$7.09 |
3.16 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.314B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
